BEST UNLIMITED TURBO LONG CERTIFICATE - ASTRAZENECA | Market Closed - Euronext Paris 12:30:00 2024-05-02 EDT | ||
| 7.147 EUR | +4.08% |
|
| Current month | +4.08% | ||
| 1 month | +89.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 7.147 | +4.08% | 109 |
| 24-04-30 | 6.867 | -0.81% | 103 |
| 24-04-29 | 6.923 | -1.40% | 112 |
| 24-04-26 | 7.021 | +1.98% | 109 |
| 24-04-25 | 6.885 | +28.16% | 112 |
Real-time Euronext Paris
Last update May 02, 2024 at 12:30 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| PW33S | |
| ISIN | DE000SF1DXF5 |
| Date issued | 2021-06-11 |
| Strike | 9,110 p |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.81 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.926 € |
|---|---|
| Lowest since issue | 0.125 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.9
USD
Average target price
164.5
USD
Spread / Average Target
+8.29%
- Stock Market
- Certificates
- PW33S Certificat
